Moneycontrol
    Moneycontrol PRO
    Loans
    Loans

    Dr Reddys Labs

    Jump to

    • Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y

    • Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y

    • Neutral Dr Reddys Labs; target of Rs 1250: Motilal Oswal

      Motilal Oswal recommended Neutral rating on Dr Reddys Labs with a target price of Rs 1250 in its research report dated December 12, 2025.

    • Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y

    • Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y

    • Neutral Dr Reddys Labs; target of Rs 1250: Motilal Oswal

      Motilal Oswal recommended Neutral rating on Dr Reddys Labs with a target price of Rs 1250 in its research report dated October 25, 2025.

    • Neutral Dr Reddys Labs; target of Rs 1190: Motilal Oswal

      Motilal Oswal recommended Neutral rating on Dr Reddys Labs with a target price of Rs 1190 in its research report dated July 23, 2025.

    • Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y

    • Dr Reddys Labs Standalone March 2025 Net Sales at Rs 5,562.90 crore, up 8.97% Y-o-Y

    • Dr Reddys Labs Consolidated March 2025 Net Sales at Rs 8,528.40 crore, up 19.89% Y-o-Y

    • Dr Reddy's Labs Q4 Results: Net profit rises 22% to Rs 1,594 crore on strong generics, NRT boost, beats estimates

      Dr Reddy's Labs Q4 results: Revenue from North America rose 9% to Rs 3,559 crore, while revenue in Europe more than doubled to Rs 1,276 crore

    • Dr Reddys Labs Consolidated December 2024 Net Sales at Rs 8,381.20 crore, up 15.81% Y-o-Y

    • Neutral Dr Reddys Labs; target of Rs 1330: Motilal Oswal

      Motilal Oswal recommended Neutral rating on Dr Reddys Labs with a target price of Rs 1330 in its research report dated January 24, 2025.

    • Dr Reddys Labs Standalone December 2024 Net Sales at Rs 5,015.00 crore, up 22.23% Y-o-Y

    • Dr Reddy's surges 4% on Nuvama upgrade to 'buy', bullishness on efforts to mitigate Revlimid expiry impact

      Nuvama expect Dr Reddy's new launches--Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

    • Dr Reddy's Labs top Nifty gainer, surges 9% in three sessions

      Nomura recently upgraded its rating on Dr Reddy's to "buy," lauding the company's increased capex in FY25, which it sees as a strong indication of the company's commitment to future growth.

    • Dr Reddy's launches cancer drug Toripalimab in India

      In 2023, Dr Reddy's signed a licensing and commercialization agreement with Shanghai Junshi Biosciences for Toripalimab which granted the drugmaker exclusive rights to develop and market Toripalimab in 21 countries.

    • Gainers & Losers: Stocks and sectors that moved the most on November 6

      Emkay Institutional Equities analysts suggested that a Republican sweep may trigger an initial rally and short-term boost for India from foreign inflows, though sustained gains will depend on earnings growth and stable valuations amidst challenges.

    • Dr Reddys Labs Consolidated September 2024 Net Sales at Rs 8,038.20 crore, up 16.45% Y-o-Y

    • Dr Reddys Labs Standalone September 2024 Net Sales at Rs 6,696.30 crore, up 38.39% Y-o-Y

    • Lack of strong launch pipeline keep brokerages neutral over Dr Reddy's Labs

      Even though Dr Reddy's showcased decent earnings performance after adjusting for one-offs in Q2, the absence of a strong launch pipeline keep brokerages cautious over its growth outlook.

    • Dr Reddys Labs Consolidated June 2024 Net Sales at Rs 7,696.10 crore, up 13.88% Y-o-Y

    • Dr Reddys Labs Standalone June 2024 Net Sales at Rs 5,841.20 crore, up 7.43% Y-o-Y

    • Dr Reddys Labs Standalone March 2024 Net Sales at Rs 5,104.80 crore, up 12.09% Y-o-Y

    • Neutral Dr Reddy’s Labs; target of Rs 6,070: Motilal Oswal

      Motilal Oswal recommended accumulate rating on Dr Reddy’s Labs with a target price of Rs 6,070 in its research report dated May 07, 2024.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347